ABSTRACT
Whether to restart or continue the series when anthrax vaccine doses are missed is a frequent medical management problem. We applied the noninferiority analysis model to this prospective study comparing the Bacillus anthracis protective antigen (PA) IgG antibody response and lethal toxin neutralization activity at day 28 to the anthrax vaccine adsorbed (AVA) (Biothrax®) administered on schedule or delayed. A total of 600 volunteers were enrolled: 354 in the on-schedule cohort; 246 in the delayed cohort. Differences were noted in immune responses between cohorts (p<0.0001) and among the racial categories (p<0.0001). Controlling for covariates, the delayed cohort was non-inferior to the on-schedule cohort for the rate of 4-fold rise in both anti-PA IgG concentration (p<0.0001) and TNA ED50 titers (p<0.0001); as well as the mean log10-transformed anti-PA IgG concentration (p<0.0001) and the mean log10-transformed TNA ED50 titers (p<0.0001). Providing a missed AVA dose after a delay as long as 5-7 years, elicits anti-PA IgG antibody and TNA ED50 responses that are robust and non-inferior to the responses observed when the 6-month dose is given on-schedule. These important data suggest it is not necessary to restart the series when doses of the anthrax vaccine are delayed as long as 5 or more years.
Subject(s)
Anthrax Vaccines/administration & dosage , Anthrax/prevention & control , Antibody Formation , Immunization Schedule , Adolescent , Adult , Antibodies, Bacterial/blood , Antibodies, Neutralizing/blood , Antigens, Bacterial/immunology , Bacillus anthracis , Bacterial Toxins/immunology , Female , Humans , Immunoglobulin G/blood , Male , Middle Aged , Neutralization Tests , Prospective Studies , Time Factors , Young AdultSubject(s)
Arenaviridae Infections/prevention & control , Junin virus/immunology , Viral Vaccines , Animals , Arenaviridae Infections/history , Clinical Trials as Topic , Drug Evaluation, Preclinical , Female , History, 20th Century , Humans , Male , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/adverse effects , Vaccines, Attenuated/immunology , Viral Vaccines/administration & dosage , Viral Vaccines/adverse effects , Viral Vaccines/history , Viral Vaccines/immunologyABSTRACT
Argentine hemorrhagic fever (AHF) is a potentially lethal infection in Argentina. The case-fatality ratio is >15%, but treatment reduces the mortality rate to <1%. Diagnosis is based on clinical and laboratory criteria, but no case definition has been validated. A chart review was conducted for patients hospitalized with suspected AHF. Individuals with a fourfold rise in antibody titer were classified as cases. The combination of a platelet count of <100,000/mm3 and a white blood cell (WBC) count of <2,500/mm3 had a sensitivity and specificity of 87% and 88%, respectively, thus suggesting that the use of these criteria in a case definition would be helpful for epidemiological studies of AHF. The combination of a platelet count of <100,000/mm3 and a WBC count of <4,000/mm3 had a sensitivity of 100% and a specificity of 71%; the use of these criteria in a case definition should be helpful for screening patients for therapy with immune plasma in the region where AHF is endemic.
Subject(s)
Arenaviridae Infections/diagnosis , Hemorrhagic Fever, American/diagnosis , Junin virus/isolation & purification , Adult , Antibodies, Viral/blood , Arenaviridae Infections/blood , Argentina , Female , Hemorrhagic Fever, American/blood , Humans , Junin virus/immunology , Leukocyte Count , Male , Platelet Count , Risk Factors , Sensitivity and SpecificityABSTRACT
Argentine hemorrhagic fever (AHF), caused by the arenavirus Junin, is a major public health problem among agricultural workers in Argentina. A prospective, randomized, double-blind, placebo-controlled, efficacy trial of Candid 1, a live attenuated Junin virus vaccine, was conducted over two consecutive epidemic seasons among 6500 male agricultural workers in the AHF-endemic region. Twenty-three men developed laboratory-confirmed AHF during the study; 22 received placebo and 1 received vaccine (vaccine efficacy 95%; 95% confidence interval [CI], 82%-99%). Three additional subjects in each group developed laboratory-confirmed Junin virus infection associated with mild illnesses that did not fulfill the clinical case definition for AHF, yielding a protective efficacy for prevention of any illness associated with Junin virus infection of 84% (95% CI, 60%-94%). No serious adverse events were attributed to vaccination. Candid 1, the first vaccine for the prevention of illness caused by an arenavirus, is safe and highly efficacious.
Subject(s)
Arenaviruses, New World/immunology , Hemorrhagic Fever, American/prevention & control , Hemorrhagic Fever, American/therapy , Vaccines, Attenuated/therapeutic use , Viral Vaccines/therapeutic use , Adolescent , Adult , Agricultural Workers' Diseases/prevention & control , Agricultural Workers' Diseases/therapy , Agricultural Workers' Diseases/virology , Animals , Antibodies, Viral/analysis , Antibodies, Viral/immunology , Arenaviruses, New World/growth & development , Argentina , Cells, Cultured , Chlorocebus aethiops , Double-Blind Method , Hemorrhagic Fever, American/diagnosis , Humans , Male , Middle Aged , Prospective Studies , Seasons , Vaccines, Attenuated/adverse effects , Vero Cells , Viral Vaccines/adverse effectsABSTRACT
Oliveros virus is an agent isolated in cell culture from Bolomys obscurus (Rodentia, Muridae, Sigmodontinae) captured on the central Argentine pampa. Oliveros virus was shown to be related to members of the Tacaribe complex of the family Arenaviridae by immunofluorescent antibody (IFA) tests, electrophoretic pattern of viral proteins, and morphology as observed by electron microscopy. It was distinct from 12 other arenaviruses by a combination of plaque-reduction neutralization tests, comparison of endpoint titers among cross-IFA tests, and comparison of viral RNA sequence data. This agent is the third new arenavirus from South America described within the last three years.
Subject(s)
Arenaviruses, New World/classification , Disease Reservoirs , Hemorrhagic Fever, American/virology , Rodent Diseases/virology , Sigmodontinae/virology , Animals , Animals, Suckling , Arenaviruses, New World/isolation & purification , Arenaviruses, New World/physiology , Argentina , Chlorocebus aethiops , Cross Reactions , Cytopathogenic Effect, Viral , Electrophoresis, Polyacrylamide Gel , Fluorescent Antibody Technique , Mice , Mice, Inbred ICR , Microscopy, Electron , Neutralization Tests , Vero Cells , Viral Proteins/analysis , Virion/ultrastructureABSTRACT
A vaccine against Argentine hemorrhagic fever, the "mal de los rastrojos" of the pampas, has been a dream of physicians and scientists involved with the disease since its recognition in the 1950s. Several killed and live immunogens have been produced and tested in pursuit of this goal, none of which has proved suitable for widespread human use. Recently, a new live-attenuated Junin virus vaccine, Candid #1, was developed through a cooperative international effort. Testing conducted to date indicates that this vaccine holds considerable promise.
Subject(s)
Arenaviruses, New World/immunology , Hemorrhagic Fever, American/prevention & control , Viral Vaccines , Animals , Humans , Vaccines, Attenuated , Vaccines, InactivatedABSTRACT
A refined, complement-enhanced, plaque-reduction neutralization test was developed for measuring neutralizing antibodies against Junin (Argentine hemorrhagic fever) virus. The assay measured neutralizing antibodies after natural as well as vaccine-induced Junin virus infections. Among vaccinated individuals, titers were 2-4-fold higher than those obtained with conventional assays, without loss of specificity. Enhanced sensitivity was achieved by using a standardized complement source (vs human or animal serum) for virus dilution, incubation of virus-serum mixtures at 36 degrees C for 2 h (vs overnight at 4 degrees C) prior to plaque assay, control of age and density of cell monolayers, and variation in overlay conditions.
